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Summary.-The effects of methotrexate (MTX) and 2,4-diamino-5-(3',4'-dichloro-
phenyl)-6-methylpyrimidine (BW50197) on the colony forming ability of L5178Y cells
were compared. Two sub-lines of cells were used, one sensitive to methotrexate
and the other resistant. In addition, the inhibitory effects of BW50197 against
dihydrofolate reductase (DHFR) extracted from the MTX resistant-cells were com-
pared with those of MTX and pyrimethamine. It was found that although BW50197
was a less effective inhibitor of DHFR than MTX, it was superior to MTX at high
concentrations in killing MTX resistant cells, and this superiority increased with the
time of exposure to the drugs. These findings suggest that (a) when antifolate
compounds are screened for antitumour activity it is insufficient simply to assess
them on the basis of their ability to inhibit DHFR and (b) BW50197 should be given
clinically so as to achieve the highest possible tissue concentration for the longest
possible time consistent with the safety of the patient.
WHILE testing the effect of a series of
diaminopyrimidines for antitumour
activity against transplantable mouse
tumours, Clarke et al. (1952) showed that
one of this class of agents, 2,4-diamino-5-
(3',4'-dichlorophenyl)-6-methylpyrimidine
(BW50197) was particularly effective in
inhibiting the growth of the sarcoma 180.
Further studies showed that this com-
pound was also effective in controlling
leukaemia (Burchenal et al., 1952) and the
growth of the Ehrlich ascites tumour
(Sugiura, 1953) in mice, and that it
modified the growth of the chick embryo
(Karnofsky, unpublished data). Under
the conditions of testing, BW50197 was
the pyrimidine analogue most effective in
inhibiting tumour growth. Subsequently
Murphy et al. (1954) showed in a clinical
study that BW50197 produced haemato-
logical improvement in 3 out of 12 children
with acute leukaemia. Our interest in
BW50197 was stimulated by the observa-
tion by Nichol (1968) that inhibition of a
methotrexate resistant tumour (the
Walker carcinoma 256) could be achieved
by this drug which showed a more
favourable therapeutic index against this
tumour than pyrimethamine (Mishra,
Rosen and Nichol, 1967; Sotobayashi,
Rosen and Nichol, 1966). Furthermore
Geils et al. (1971) showed that pyri-
methamine was effective in controlling
some cases of meningeal leukaemia in
man. Because diaminopyrimidines had
been shown to possess antitumour activity
and since BW50197 appeared superior in
certain experimental systems, we felt that
this compound merited further study. In
this report we present the results of the
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effects of BW50197 and methotrexate
(MTX) on MTX-sensitive and MTX-
resistant lines of L5178Y lymphoblasts in
culture.
MATERIALS AND METHODS
Chemicals.-BW50197 and pyrimetha-
mine sulphate were kindly provided by Dr
A. H. Griffith of the Wellcome Research
Laboratories, Beckenham, England, and
MTX was obtained from Lederle Labora-
tories. Reduced nicotinamide adenine-
dinucleotide-phosphate (NADPH) was ob-
tained from Boehringer GMBH, Dl-L-tetra-
hydrofolic acid from Sigma Chemical Co. and
NToble agar from Difco Laboratories, Detroit,
U.S.A. Other chemicals were purchased
from Hopkin and Williams Ltd, or British
Drug Houses Ltd, AnalaR grades being used
where available.
Tumour cells.-L5178Y cells were grown
in suspension culture in Fischer's medium for
leukaemic cells of mice (Grand Island
Biological Co., California) containing 10%
foetal calf serum (Flow Laboratories, Glas-
gow, U.K.). Two sub-lines were used: the
methotrexate sensitive, inhibited by con-
tinuous exposure to 2 x 10-8 mol/l MTX, and
an MTX resistant sub-line produced by con-
tinuous exposure to sublethal concentrations
of the drug, inhibited when subcultured in
2 x 10-6 mol/l MTX. Both cell lines had
similar growth rates, with a doubling time of
approximately 24 hours during the exponen-
tial growth phase.
Colonyforming ability.-The colony form-
ing assays were performed according to a
modification by Goldenberg (personal com-
munication 1972) of the method of Chu and
Fischer (1968) as follows: Initial dose response
curves of the cells growing in suspension
culture in the presence of varying concentra-
tions ofMTX and BW50197 were obtained by
direct cell counts using a haemacytometer.
From these data, the approximate log cell kill
produced by each drug concentration for the
2 cell lines was calculated. For the cell
viability assays the concentration of cells per
ml which were subsequently added to each
Falcon tissue culture tube containing cloning
medium was then adjusted to take into
account the log cell kill predicted, so that
approximately 100 colonies per culture tube
were obtained for counting after 8-10 days
incubation at 37TC. This method removes
any possible inaccuracy which might be
involved in counting only small numbers of
colonies where maximal cell kill is achieved,
which occurs when the conventional method
of adding cells at a fixed concentration to the
culture tubes, irrespective of the drug con-
centrations, is used. Under these conditions
a 66% cloning efficiency for control cells was
obtained.
The data, expressed in survival curves,
represents the mean value of colonv counts of
5 replicate cultures expressed as a percentage
of the control (non-treated) cultures. Each
experiment was performed in duplicate and
the scatter at any point never exceeded 20%.
Estimation of dihydrofolate reductase.-
Cells in logarithmic growth were counted,
centrifuged at 350 g for 15 min at 40C. wNashed
twice in phosphate buffered saline and
recentrifuged. The washed cells wN-ere sus-
pended in 0 05 ,umol/l Tris-HCl buffer pH 7-2
to a final concentration of 108 cells per ml and
disrupted by sonication for 30 seconds at
2 mc/sec (M.S.E. ultrasonicator). Insoluble
material was removed by centrifuigation at
2500 g for 30 min at 4°C. Soluble protein in
this lysate was 92 mg per 109 cells, as deter-
mined by the method of Lowry et al. (1951).
Dihydrofolate reductase activity in the
supernatant solution was assayed by the
method of Mathews and Huennekens (1963).
RESULTS
Fig. 1 shows the results of a 24 hour
exposure to MTX and BW50197 on the
colony forming ability of both sensitive
and resistant lines of L5178Y cells. The
survival curves for both cell lines with
increasing concentrations of MTX (Fig.
IA) are characterized by a steep initial fall,
followed by a tendency to flatten out.
The initial decrease in the survival of
resistant cells is not observed until an
extracellular concentration in excess of
10-7 mol/l is achieved. Fig. lB shows
that BW50197 is less effective oI a molar
basis than MTX at low concentrations
against both sensitive and resistant cell
lines. However, the shape of the survival
curve is different from those of MTX.
Exposure to higher doses of BWA50197
produced an almost linear fall in survival
which resulted in a considerably greater
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Fic. IA. Effects of a 24 houi exposure to MITX
on the colony forming ability of sensitive and
resistant L5178Y cells. At no point did the
scatter exceed 2000.
reduction in cell viability than could be
achieved by MTX in either cell line at
10-4 mol/l concentrations. Thus at equi-
m-olar concentrations (10-4 mol/l)
BiW50197 reduced the viability of the
resistant (RL5178Y) cells to approxi-
mnately 2% whereas MTX reduced survival
only to 10%. The presence of a shoulder
in the survival curves for resistant cells
exposed to BW50197 indicates that re-
dluction in cell viability does not occur
until a critical extracellular concentration
of the drug is achieved. There was no
evidence of any tendency for the survival
curves to flatten out at high drug con-
centrations for either cell line exposed to
BW50197. Concentrations higher than
10-4 mol7l could not be tested because of
the insolubility of BW50197.
When the exposure time of the cells to
the drugs is increased to 36 hours, the
Molarity of BW50197
FIG. lB.-Effects of a 24 hour exposure to
13W50197 on the colony forming ability of
sensitive and resistant L5178Y cells. At no
point did the scatter exceed 20%.
difference in the survival curves using MTX and BW50197 is even more marked
(Fig. 2). Under these circumstances
BW50197 at 10-4 mol/l produces a far
greater reduction in cell viability (to less
than 1%) ofthe RL5178Y cells than could
be achieved by an equimolar concentra-
tion of MTX. Thus the superiority of
BW50197 over MTX against the resistant
cells increases with the time of exposure to
the drug. Both drugs are very stable
under the in vitro conditions used, and are
not metabolized (Griffith, personal com-
munication 1972).
Acomparison ofthe effects ofBWr50197
on crude extracts of dihydrofolate reduct-
ase from RL50197 cells with that ofknown
antifolates such as MTX and pyrimetha- mine yielded the results shown in the
following table:
Thus, although BW50197 is a less
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FiG. 2.-Effects of a 36 hour exposure to MTX
and BW50197 on the colony forming ability
of L5178Y cells. At no point did the scatter
exceed 20%.
effective inhibitor of DHFR than is MTX,
in this system it shows activity comparable
with that of pyrimethamine. These data
support conclusions from earlier studies
that BW50197 acts as a folate antagonist
(Murphy et al., 1954; Hamilton et al.,
1952).
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Comparison of the Inhibitory Effects of
3 Antifolates on Dihydrofolate Reductase
from MTX Resistant L5178Y Lympho-
blasts*
Inhibitor
MITX
Pyrimethamine
BW50197
Concentration of
inhibitor for 50 %
inhibition
5 x 10-9 mol/l
1 8 x 10-5 mol/l
2-4x 10-5mol/l
* Specific activity of dihydrofolate reductase was
1 9 International Units (i.u.) pei 109 cells (1 i.u. of
enzyme is equivalent to 1 ,imol of substrate reduced
per min.
DISCUSSION
The resistant L5178Y cells used in
these experiments are derived from a cell
line considered to be resistant to MTX by
virtue of impaired transport of MTX
across the cell membrane (Harrap et al.,
1971). These cells can still be killed
provided that a sufficient extracellular
concentration of the drug can be main-
tained for a long enough time (Harrap et
al., 1971). Clinically, however, a pro-
longed exposure to MTX is associated
with severe toxicity to normal proliferat-
ing systems such as the bone marrow and
gut (Bergsagel, personal communication
1970), although very high concentrations
can safely be given over short periods of
time (Goldie, Price and Harrap, 1972;
Djerassi et al., 1,972). However, although
BW50197 does produce haematological
toxicity, it can be given over much longer
periods than MTX (Murphy et al., 1954).
Therefore, since human tumours exist
which are resistant to MTX by virtue of a
transport defect (Kessel, Hall andRoberts,
1968), BW50197 might be a preferable
drug for treatment, particularly since its
superiority over MTX in this situation
increases with time. In addition, the
bone marrow toxicity of BW50197, as of
MTX, can be preventedby the administra-
tion of folinic acid (Calcium Leucovorin,
Lederle) (Clarke et al., 1952), which sup-
ports the suggested antifolate action ofthe
drug.
From the results described above, two
conclusions emerge which may have con-
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siderable experimental and clinical signifi-
cance. First, the practice ofassessing the
potential antitumour effects of various
antifolates simply in terms of their ability
to inhibit DHFR is inadequate. We have
shown that BW50197 is a much less
effective inhibitor of DHFR than is MTX.
Even so, BW50197 is a markedly superior
drug for killing MTX resistant cells.
There are two possible explanations to
account for this finding: (1) the critical
site of action of BW50197 may be at some
enzymatic locus of folate metabolism
other than DHFR or (2) BW50197 may be
transported by a different mechanism than
MTX. Although definite proofis lacking,
we are inclined towards the second
explanation, forwhich some circumstantial
evidence exists (Goldie, Furness and Price,
1973; Wood, Ferone and Hitchings, 1961).
Whatever the explanation, the important
poinit is that cell viability assays are
essential in the overall assessment of the
biological activity of these agents. If
agents are rejected purely on the basis of
their inferior activity against DHFR, it is
possible that potentially valuable anti-
tumour agents will be missed.
The second significant conclusion from
these results is that far greater reduction
in the cell viability of resistant cells is
achieved when very high doses of
BW50197 are given, and that this effec-
tiveness increases with time. This sug-
gests that, in contrast to previous practice,
t,he maximum possible dose of BW50197
should be given for the longest possible
time in MTX resistant tumours.
BWA50197 has a much longer half-life
(180-200 hours) than MTX and is con-
centrated in certain tissues, so that tissue
concentrations greater than plasma con-
centrations can be achieved. There are,
however, certain practical obstacles to this
course. For example, BW50197 reaches
very high concentrations in the brain
(Stickney et al., 1973) and so may produce
convulsions. Also, a protracted and ex-
pensive course of folinic acid might be
necessary to prevent bone marrowtoxicity.
In spite of this, it might be possible to
administer BW50197 using the " kill and
rescue " technique currently employed for
MTX and suggested for pyrimethamine
(Goldie et al., 1973). In any event, these
findings confirm the potential usefulness of
diaminopyrimidines and we think it
possible that BW50197, given carefully,
might be effective in certain tumours
resistant to MTX. We propose to carry
out clinical studies along the lines indi-
cated above.
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